BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

—ORLADEYO net revenue expected to be between $515-$535 million in 2025—

—Total revenue (including RAPIVAB^®) expected to be between $540-$560 million in 2025—